A provider survey assessing fetal impact of CFTR modulator use in males with CF during assisted and unassisted reproduction and partner pregnancy
Journal of Cystic Fibrosis · 2024
DOI: 10.1016/j.jcf.2023.10.022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2024. Verfasst von Jennifer L Taylor-Cousar und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Jewish Health, Departments of Medicine and Pediatrics; University of Colorado Anschutz Medical Campus, Departments of Medicine and Pediatric…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Reproductive Techniques, Assisted. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Health, Cystic Fibrosis Foundation, University of Texas Southwestern Medical Center.
Abstract (Originalsprache)
BACKGROUND: Most males with cystic fibrosis (mwCF) are infertile but with CF transmembrane conductance regulator (CFTR) modulator-conferred benefits, more are utilizing assisted reproductive technologies (ART). Administration of normal human doses of modulators in animal reproductive models caused no genotoxicity; no human data exists. Potential health decline following modulator discontinuation makes the decision to withhold therapy during reproduction challenging. METHODS: From August-October 2021, international CF clinicians completed an anonymous questionnaire regarding mwCF who used modulators during reproduction. RESULTS: We received 42 surveys for mwCF with partner pregnancies. Forty of 42 mwCF utilized ART; 35 continued modulators during sperm retrieval and 40/42 during partner pregnancy. One of four males who discontinued modulators experienced clinical deterioration. First trimester miscarriages occurred in 11.9 % of partner pregnancies. No congenital anomalies were reported. CONCLUSIONS: Use of CFTR modulators during reproduction and partner pregnancy in mwCF did not result in a higher-than-expected miscarriage rate nor congenital anomalies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Jewish Health, Departments of Medicine and Pediatrics; University of Colorado Anschutz Medical Campus, Departments of Medicine and Pediatrics. Electronic address: Taylor-CousarJ@NJHealth.org.
- National Jewish Health, Clinical Research Services.
- University of Sydney, Discipline of Medicine.
- University of Texas Southwestern, Department of Medicine.
- University Hospital Southhampton NHS Trust.
- Johns Hopkins University, Department of Medicine.
Förderung
- National Institutes of Health
- Cystic Fibrosis Foundation
- University of Texas Southwestern Medical Center
Zitieren
APA
Taylor-Cousar, J. L., Janney, R., Middleton, P. G., Jain, R., Nightingale, J., West, N. E., Shteinberg, M., Velez, D., & Kazmerski, T. M. (2024). A provider survey assessing fetal impact of CFTR modulator use in males with CF during assisted and unassisted reproduction and partner pregnancy. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2023.10.022
Vancouver
Taylor-Cousar JL, Janney R, Middleton PG, Jain R, Nightingale J, West NE, et al. A provider survey assessing fetal impact of CFTR modulator use in males with CF during assisted and unassisted reproduction and partner pregnancy. Journal of Cystic Fibrosis. 2024. doi:10.1016/j.jcf.2023.10.022
BibTeX
@article{TaylorCousar2024,
author = {Taylor-Cousar, Jennifer L and Janney, Rachel and Middleton, Peter G and Jain, Raksha and Nightingale, Julia and West, Natalie E and Shteinberg, Michal and Velez, Danielle and Kazmerski, Traci M},
title = {A provider survey assessing fetal impact of CFTR modulator use in males with CF during assisted and unassisted reproduction and partner pregnancy},
journal = {Journal of Cystic Fibrosis},
year = {2024},
doi = {10.1016/j.jcf.2023.10.022}
}
EUVIMED